Multiple imputation methodology is reflective of secukinumab efficacy in real clinical practice: Data from the FIXTURE and ERASURE studies in moderate to severe plaque psoriasis

被引：0
|
作者：
Langley, Richard [1 ]
Reich, Kristian [2 ,3 ]
Papavassilis, Charms [4 ]
Fox, Todd [4 ]
Gong, Yankun [5 ]
Guettner, Achim [4 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] SCIderm Res Inst, Hamburg, Germany
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P047
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
    Alan Menter
    Jennifer C. Cather
    Michael Jarratt
    Xiangyi Meng
    Adriana Guana
    Judit Nyirady
    Dermatology and Therapy, 2016, 6 : 639 - 647
  • [42] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
    Pariser, David
    Frankel, Ellen
    Schlessinger, Joel
    Poulin, Yves
    Vender, Ronald
    Langley, Richard G.
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    DERMATOLOGY AND THERAPY, 2018, 8 (01) : 17 - 32
  • [43] Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies
    Menter, Alan
    Cather, Jennifer C.
    Jarratt, Michael
    Meng, Xiangyi
    Guana, Adriana
    Nyirady, Judit
    DERMATOLOGY AND THERAPY, 2016, 6 (04) : 639 - 647
  • [44] Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Abortion and Transitions between Pre-treatment and Secukinumab Treatment
    Kraehn-Senftleben, G.
    von Kiedrowski, R.
    Korber, A.
    Pinter, A.
    Heidlas, O.
    Bachhuber, T.
    Kasparek, T. R.
    Thaci, D.
    Amon, U.
    Augustin, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 138 - 139
  • [45] Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
    Rattanakaemakorn, Ploysyne
    Chevaisrakul, Parawee
    Wongpraparut, Chanisada
    Chiowchanwisawakit, Praveena
    Tovanabutra, Napatra
    Tantiwong, Pimchanok
    Amornpinyo, Warayuwadee
    Chakkavittumrong, Panlop
    Hanvivadhanakul, Punchong
    Chaiamnuay, Sumapa
    Laodheerasiri, Supapat
    Pattamadilok, Bensachee
    Choonhakarn, Charoen
    Mahakkanukrauh, Ajanee
    Aiewruengsurat, Duangkamol
    Sangmala, Siripan
    Pretikul, Nisa
    Sumethkul, Kittiwan
    Satpanich, Panchalee
    Boonsiri, Metavee
    Sangob, Naruemon
    Asawanonda, Pravit
    DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3229 - 3241
  • [46] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Gaojie Li
    Yuanxia Gu
    Qin Zou
    Yiyi Wang
    Yue Xiao
    Dengmei Xia
    Tongying Zhan
    Xingli Zhou
    Qian Wang
    Wei Yan
    Wei Li
    Dermatology and Therapy, 2022, 12 : 2105 - 2115
  • [47] Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study
    Li, Gaojie
    Gu, Yuanxia
    Zou, Qin
    Wang, Yiyi
    Xiao, Yue
    Xia, Dengmei
    Zhan, Tongying
    Zhou, Xingli
    Wang, Qian
    Yan, Wei
    Li, Wei
    DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2105 - 2115
  • [48] Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study
    Georgakopoulos, J. R.
    Ighani, A.
    Zhou, L. L.
    Yeung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (01) : E32 - E34
  • [49] Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study
    Rompoti, Natalia
    Katsimbri, Pelagia
    Kokkalis, Georgios
    Boumpas, Dimitrios
    Ikonomidis, Ignatios
    Theodoropoulos, Konstantinos
    Rigopoulos, Dimitris
    Papadavid, Evangelia
    DERMATOLOGIC THERAPY, 2019, 32 (05)
  • [50] Secukinumab shows similar efficacy across baseline Dermatology Life Quality Index subgroups (≤ 10 or > 10) in patients with moderate-to-severe psoriasis in two pivotal phase III studies (FIXTURE and ERASURE)
    Williams, R.
    Tomlinson, M.
    Armendariz, Y.
    Allen, F.
    BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 76 - 76
12345